Ionis PharmaceuticalsvsMerck & Company

IONS and MRK stock compared: price, dividend, valuation and results, from SEC filings.

IONS

Ionis Pharmaceuticals, Inc.

$27.39

Value $4.5B

+1.59%
IONS's page

MRK

Merck & Company, Inc.

$137.78

Value $341B

-3.90%
MRK's page

Ionis Pharmaceuticals (IONS) has a market value of $4.5B and Merck & Company (MRK) $341B. Over the last year, with dividends, IONS moved -62.6% and MRK +52.7%. Dividend yield: IONS none, MRK 2.47%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    IONS$4.5B

    MRK$341B

    MRK is 75 times IONS

  • Revenue, 12 months

    IONS$960M

    MRK$67.4B

    MRK is 70 times IONS

  • Net income, 12 months

    IONS-$547M

    MRK$2.5B

  • Operating margin

    IONS-58.8%

    MRK–

  • ROIC

    IONS-23.7%

    MRK3.9%

    27.6 points apart

  • P/E

    IONS–

    MRK138.9

  • Dividend yield

    IONS0.0%

    MRK2.5%

    2.5 points apart

  • 5-year return

    IONS-15.7%

    MRK+94.3%

    110.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

IONS-15.7%

MRK+94.3%

10020020222023202420252026
Returns by period
PeriodIONSWith dividendsMRKWith dividends
1 year since November 17, 2025-62.6%Price -62.6%+52.7%Price +48.4%
3 years since November 17, 2023-44.1%-17.6% a yearPrice -44.1%+48.4%+14.1% a yearPrice +35.4%
5 years since November 17, 2021-15.7%-3.4% a yearPrice -15.7%+94.3%+14.2% a yearPrice +66.8%
10 years since November 18, 2016-39.3%-4.9% a yearPrice -39.3%+216.6%+12.2% a yearPrice +133.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

IONSIonis PharmaceuticalsMRKMerck & Company

Valuation

IONSMRK
Valuation
Price$27.39$137.78
Market value$4.5B$341B
Enterprise value (EV)$4.0B$385B
P/E–138.9
P/E, 5-year median–14.8
P/B11.57.6
EV/EBIT–80.8
Free cash flow yield–4.3%

Results and growth

IONSMRK
Results and growth
Revenue, 12 months$960M$67.4B
Net income, 12 months-$547M$2.5B
Free cash flow, 12 months-$616M$14.7B
Earnings per share, 12 months-$3.32$0.98
Revenue growth, year on year33.8%1.3%
Revenue growth a year, past+5.3%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

IONSMRK
Margins and returns on capital
Gross margin98.2%71.8%
Operating margin-58.8%–
Net margin-56.9%3.6%
ROIC-23.7%3.9%
ROE-112.4%5.2%

Balance sheet

IONSMRK
Balance sheet
Cash$1.9B$9.7B
Total debt$1.6B$53.8B
Net debt / EBITDA–5.7
Interest cover-29.4×2.4×

Dividends and buybacks

IONSMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: IONS or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Ionis Pharmaceuticals or Merck & Company?

By market value, Merck & Company ($341B) is about 75.3 times Ionis Pharmaceuticals ($4.5B), at today's prices.

How did IONS and MRK stock do over the last 10 years?

Since November 18, 2016, IONS's price moved -39.3% and MRK's +133.4%. With dividends: IONS -39.3% (-4.9% a year), MRK +216.6% (+12.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, IONS or MRK?

The dividend yield at today's price is none for Ionis Pharmaceuticals and 2.47% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Ionis Pharmaceuticals or Merck & Company?

Over the last twelve months, the net margin was -56.9% for Ionis Pharmaceuticals and 3.6% for Merck & Company, and the operating margin -58.8% and –. Revenue was $960M and $67.4B.

Which is the better investment, Ionis Pharmaceuticals or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.